LIFECOME BIOCHEMISTRY CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.67 CNY | -3.25% |
|
+0.30% | -21.59% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 1,790 | 2,154 | 2,046 | 1,692 | 8,144 | 3,261 |
| Enterprise Value (EV) 1 | 1,417 | 1,838 | 1,934 | 1,885 | 8,516 | 4,140 |
| P/E ratio | 24.1 x | 38.2 x | 47.6 x | -64.9 x | -67.2 x | -14.8 x |
| Yield | 1.68% | 0.95% | 1.05% | - | - | - |
| Capitalization / Revenue | 5.2 x | 7.09 x | 6.64 x | 4.66 x | 24.7 x | 6.43 x |
| EV / Revenue | 4.11 x | 6.05 x | 6.28 x | 5.19 x | 25.8 x | 8.17 x |
| EV / EBITDA | 15.5 x | 26.5 x | 27.9 x | 95.9 x | -161 x | -70.3 x |
| EV / FCF | 45.3 x | 7.67 x | -12.7 x | -7.29 x | -18.4 x | -31.5 x |
| FCF Yield | 2.21% | 13% | -7.85% | -13.7% | -5.45% | -3.17% |
| Price to Book | 2.42 x | 2.78 x | 2.67 x | 2.36 x | 13.7 x | 8.01 x |
| Nbr of stocks (in thousands) | 156,000 | 156,000 | 153,404 | 153,404 | 153,404 | 153,404 |
| Reference price 2 | 11.48 | 13.81 | 13.34 | 11.03 | 53.09 | 21.26 |
| Announcement Date | 15/04/19 | 26/04/20 | 15/03/21 | 11/04/22 | 14/04/23 | 29/04/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 344.3 | 303.8 | 308.1 | 363.4 | 329.9 | 507 |
| EBITDA 1 | 91.64 | 69.44 | 69.4 | 19.65 | -52.83 | -58.89 |
| EBIT 1 | 62.01 | 40.98 | 39.17 | -13.96 | -116.7 | -128.2 |
| Operating Margin | 18.01% | 13.49% | 12.71% | -3.84% | -35.38% | -25.28% |
| Earnings before Tax (EBT) 1 | 87.12 | 66.01 | 48.44 | -32.35 | -134.1 | -240.9 |
| Net income 1 | 74.69 | 56.97 | 43.21 | -26.04 | -121.9 | -221.8 |
| Net margin | 21.69% | 18.75% | 14.02% | -7.17% | -36.97% | -43.75% |
| EPS 2 | 0.4769 | 0.3615 | 0.2800 | -0.1700 | -0.7900 | -1.440 |
| Free Cash Flow 1 | 31.29 | 239.6 | -151.9 | -258.8 | -464 | -131.3 |
| FCF margin | 9.09% | 78.87% | -49.3% | -71.21% | -140.67% | -25.9% |
| FCF Conversion (EBITDA) | 34.14% | 345.04% | - | - | - | - |
| FCF Conversion (Net income) | 41.89% | 420.57% | - | - | - | - |
| Dividend per Share 2 | 0.1923 | 0.1308 | 0.1400 | - | - | - |
| Announcement Date | 15/04/19 | 26/04/20 | 15/03/21 | 11/04/22 | 14/04/23 | 29/04/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | 193 | 372 | 878 |
| Net Cash position 1 | 374 | 316 | 112 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | 9.827 x | -7.038 x | -14.91 x |
| Free Cash Flow 1 | 31.3 | 240 | -152 | -259 | -464 | -131 |
| ROE (net income / shareholders' equity) | 10.4% | 7.48% | 5.55% | -3.54% | -18.6% | -43.9% |
| ROA (Net income/ Total Assets) | 4.97% | 2.83% | 2.47% | -0.78% | -5.84% | -5% |
| Assets 1 | 1,502 | 2,016 | 1,749 | 3,331 | 2,089 | 4,437 |
| Book Value Per Share 2 | 4.750 | 4.960 | 4.990 | 4.680 | 3.880 | 2.650 |
| Cash Flow per Share 2 | 0.4400 | 0.7300 | 1.270 | 0.6400 | 0.1500 | 0.5400 |
| Capex 1 | 48.9 | 126 | 254 | 357 | 137 | 465 |
| Capex / Sales | 14.21% | 41.35% | 82.36% | 98.29% | 41.63% | 91.62% |
| Announcement Date | 15/04/19 | 26/04/20 | 15/03/21 | 11/04/22 | 14/04/23 | 29/04/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -21.59% | 354M | |
| -14.44% | 77.05B | |
| +25.88% | 3.73B | |
| +0.70% | 3.33B | |
| +16.39% | 1.69B | |
| -8.82% | 1.52B | |
| -22.51% | 1.3B | |
| -3.03% | 1.27B | |
| -10.11% | 1.18B | |
| +4.27% | 1.09B |
- Stock Market
- Equities
- 002868 Stock
- Financials Lifecome Biochemistry Co.,Ltd.
